Open AccessBiochemical effects of irbesartan in experimental diabetic nephropathy
Author(s) -
Raju Vaishya,
Jasbir Singh,
Harbans Lal
Publication year - 2009
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.59922
Subject(s) - irbesartan , medicine , endocrinology , diabetic nephropathy , renal hypertrophy , renal function , diabetes mellitus , creatinine , glomerulosclerosis , streptozotocin , proteinuria , kidney , blood pressure
Diabetic nephropathy (DN) is one of the most common causes of end-stage renal failure. The pathogenesis of progressive renal damage is multifactorial and the mechanism by which hyperglycemia causes microangiopathy in diabetic glomeruli is still poorly understood. Because the renin angiotensin system has been reported to be an important contributory factor in the pathophysiology of DN, exogenous administration of angiotensin II receptor antagonist may be beneficial in counteracting some biochemical or functional changes of DN.